Biotech Patents May Be Easier To Get Under Revised PTO Guidance
This article was originally published in The Gray Sheet
Yielding to industry pressure, Patent and Trademark Office says both structural and functional changes to what exists in nature should to be considered in assessing patent claims.
You may also be interested in...
Development of products derived from natural sources will be deterred by PTO’s factor-based approach to patent eligibility, firms contend, noting special concern about examples given in the office’s recent guidance document.
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.